• Title/Summary/Keyword: vaccine efficacy

Search Result 242, Processing Time 0.026 seconds

Mucosal Immunization with Recombinant Adenovirus Encoding Soluble Globular Head of Hemagglutinin Protects Mice Against Lethal Influenza Virus Infection

  • Kim, Joo Young;Choi, Youngjoo;Nguyen, Huan H.;Song, Man Ki;Chang, Jun
    • IMMUNE NETWORK
    • /
    • v.13 no.6
    • /
    • pp.275-282
    • /
    • 2013
  • Influenza virus is one of the major sources of respiratory tract infection. Due to antigenic drift in surface glycoproteins the virus causes annual epidemics with severe morbidity and mortality. Although hemagglutinin (HA) is one of the highly variable surface glycoproteins of the influenza virus, it remains the most attractive target for vaccine development against seasonal influenza infection because antibodies generated against HA provide virus neutralization and subsequent protection against the virus infection. Combination of recombinant adenovirus (rAd) vector-based vaccine and mucosal administration is a promising regimen for safe and effective vaccination against influenza. In this study, we constructed rAd encoding the globular head region of HA from A/Puerto Rico/8/34 virus as vaccine candidate. The rAd vaccine was engineered to express high level of the protein in secreted form. Intranasal or sublingual immunization of mice with the rAd-based vaccine candidates induced significant levels of sustained HA-specific mucosal IgA and IgG. When challenged with lethal dose of homologous virus, the vaccinated mice were completely protected from the infection. The results demonstrate that intranasal or sublingual vaccination with HA-encoding rAd elicits protective immunity against infection with homologous influenza virus. This finding underlines the potential of our recombinant adenovirus-based influenza vaccine candidate for both efficacy and rapid production.

Protective efficacy of a novel multivalent vaccine in the prevention of diarrhea induced by enterotoxigenic Escherichia coli in a murine model

  • Zhao, Hong;Xu, Yongping;Li, Gen;Liu, Xin;Li, Xiaoyu;Wang, Lili
    • Journal of Veterinary Science
    • /
    • v.23 no.1
    • /
    • pp.7.1-7.14
    • /
    • 2022
  • Background: Enterotoxigenic Escherichia coli (ETEC) infection is a primary cause of livestock diarrhea. Therefore, effective vaccines are needed to reduce the incidence of ETEC infection. Objectives: Our study aimed to develop a multivalent ETEC vaccine targeting major virulence factors of ETEC, including enterotoxins and fimbriae. Methods: SLS (STa-LTB-STb) recombinant enterotoxin and fimbriae proteins (F4, F5, F6, F18, and F41) were prepared to develop a multivalent vaccine. A total of 65 mice were immunized subcutaneously by vaccines and phosphate-buffered saline (PBS). The levels of specific immunoglobulin G (IgG) and pro-inflammatory cytokines were determined at 0, 7, 14 and 21 days post-vaccination (dpv). A challenge test with a lethal dose of ETEC was performed, and the survival rate of the mice in each group was recorded. Feces and intestine washes were collected to measure the concentrations of secretory immunoglobulin A (sIgA). Results: Anti-SLS and anti-fimbriae-specific IgG in serums of antigen-vaccinated mice were significantly higher than those of the control group. Immunization with the SLS enterotoxin and multivalent vaccine increased interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) concentrations. Compared to diarrheal symptoms and 100% death of mice in the control group, mice inoculated with the multivalent vaccine showed an 80% survival rate without any symptom of diarrhea, while SLS and fimbriae vaccinated groups showed 60 and 70% survival rates, respectively. Conclusions: Both SLS and fimbriae proteins can serve as vaccine antigens, and the combination of these two antigens can elicit stronger immune responses. The results suggest that the multivalent vaccine can be successfully used for preventing ETEC in important livestock.

Protective Efficacy and Immunogenicity of Rv0351/Rv3628 Subunit Vaccine Formulated in Different Adjuvants Against Mycobacterium tuberculosis Infection

  • Kee Woong Kwon;Tae Gun Kang;Ara Lee;Seung Mo Jin;Yong Taik Lim;Sung Jae Shin;Sang-Jun Ha
    • IMMUNE NETWORK
    • /
    • v.23 no.2
    • /
    • pp.16.1-16.19
    • /
    • 2023
  • Bacillus Calmette-Guerin (BCG) vaccine is the only licensed vaccine for tuberculosis (TB) prevention. Previously, our group demonstrated the vaccine potential of Rv0351 and Rv3628 against Mycobacterium tuberculosis (Mtb) infection by directing Th1-biased CD4+ T cells co-expressing IFN-γ, TNF-α, and IL-2 in the lungs. Here, we assessed immunogenicity and vaccine potential of the combined Ags (Rv0351/Rv3628) formulated in different adjuvants as subunit booster in BCG-primed mice against hypervirulent clinical Mtb strain K (Mtb K). Compared to BCG-only or subunit-only vaccine, BCG prime and subunit boost regimen exhibited significantly enhanced Th1 response. Next, we evaluated the immunogenicity to the combined Ags when formulated with four different types of monophosphoryl lipid A (MPL)-based adjuvants: 1) dimethyldioctadecylammonium bromide (DDA), MPL, and trehalose dicorynomycolate (TDM) in liposome form (DMT), 2) MPL and Poly I:C in liposome form (MP), 3) MPL, Poly I:C, and QS21 in liposome form (MPQ), and 4) MPL and Poly I:C in squalene emulsion form (MPS). MPQ and MPS displayed greater adjuvancity in Th1 induction than DMT or MP did. Especially, BCG prime and subunit-MPS boost regimen significantly reduced the bacterial loads and pulmonary inflammation against Mtb K infection when compared to BCG-only vaccine at a chronic stage of TB disease. Collectively, our findings highlighted the importance of adjuvant components and formulation to induce the enhanced protection with an optimal Th1 response.

Evaluation of efficacy of a commercial vaccine stress-relieving agent to reduce the adverse effects of foot-and-mouth disease vaccination site in pig (시판 백신접종 스트레스 완화제의 돼지 구제역 백신 접종부위 부작용 발생 저감 효과 평가)

  • Park, Yu-Ri;Lim, Da-Rae;Kim, Hye-Ryung;Park, Min-Ji;Kim, Bumseok;Kim, Won-Il;Hong, Chang-Ho;Kim, Sung-Nyon;Park, Choi-Kyu
    • Korean Journal of Veterinary Service
    • /
    • v.40 no.3
    • /
    • pp.177-185
    • /
    • 2017
  • In this study, we evaluated the efficacy of a commercial vaccine stress-relieving agent (Anti VS-2 injection) to reduce the adverse effects of foot-and-mouth disease (FMD) vaccination site in 120 pigs on two tested pig farms. The results showed that incidence of pig with abnormal meat, size of abnormal meat and weight of discarded abnormal meat are significantly decreased in Anti VS-2 injection-supplemented FMD vaccinated pig groups (n=60) compared to the non-supplemented FMD vaccinated pig groups (n=60) (P<0.05). And the average economic loss by discard of abnormal meat were estimated 99,382 won or 21,514 won in the non-supplemented FMD vaccinated groups or in the Anti VS-2 injection-supplemented FMD vaccinated groups, respectively, showing that the cost saving effect was 78% (77,869 won). In conclusion, it is expected to reduce the incidence and severity of abnormal meat in the FMD vaccinated pigs and to contribute not only to the reduced economic loss of pig farmers but also to the promotion of food hygiene when the Anti VS-2 injection is mixed with FMD vaccine.

Current Status of Human Papillomavirus Infection and Introduction of Vaccination to the National Immunization Program in Korea: an Overview

  • Kim, Min-A;Han, Gwan Hee;Kim, Jae-Hoon;Seo, Kyung
    • Journal of Korean Medical Science
    • /
    • v.33 no.52
    • /
    • pp.331.1-331.17
    • /
    • 2018
  • Human Papillomavirus (HPV) infection is the most common sexually transmitted infection and is associated with the development of cervical cancer. The purpose of this report is to provide the literature evidences on selecting the HPV vaccine for national immunization program (NIP) in Korea. To complete these tasks, we reviewed domestic and foreign literature on the current status of HPV infection, efficacy and effectiveness of HPV vaccine, safety of vaccine and cost effectiveness analysis of vaccination business. Given that the median age of first sexual intercourse is continuing to fall, this may have serious implications for HPV infection and cervical cancer incidence at the age of 20s. The World Health Organization recommends that the HPV vaccination should be included in the NIP being implemented in each country. Both the bivalent and quadrivalent vaccines have a 90% or greater preventive efficacy on cervical intraepithelial lesion 2-3 and cervical cancer by the HPV 16 or HPV 18. In the future, if HPV vaccination rate as part of NIP increases, it is expected that the incidence of HPV infection, genital warts, and cervical precancerous lesions will be decreased in the vaccination age group. Therefore, in order to increase the HPV vaccination rate at this point in Korea, social consensus and efforts such as the introduction and promotion of HPV vaccine to the NIP according to appropriate cost-effectiveness analysis are required.

Efficacy of Concurrent Administration of Live and Killed Newcastle Disease Vaccines in Day - Old Broiler Chicks (육용계 초생추에 대한 뉴켓슬병 생독 및 사독 백신의 동시접종 효과)

  • 최정옥;박승주;위성하
    • Korean Journal of Poultry Science
    • /
    • v.15 no.3
    • /
    • pp.193-198
    • /
    • 1988
  • In order to examine the efficacy of concurrent vaccination with live and killed Newcastle disease(ND) vaccines two types of each live($B_1$ and LaSota) and killed(gel and oil) vaccines of all commercial origin were administered either alone or simultaneously to day-old broiler chicks having maternal antibody. Live vaccines were given by conjuntival instillation in volumes of 25${\mu}\ell$ containing $10^{6.0}$ to $10^{6.3}$ median embroy infective dose(EH)) while killed vaccines were given in 0.3$m\ell$ volumes subcutaneously at the back of the neck Hemagglutination inhibition(HI) antibodies were determined at weekly intervals until 8 weeks of age and protection rate was determined at 4 and 8 week of age by challenge inoculation with virulent ND virus(NDV). During the 8 weeks experimental period concurrent administration of live and oil vaccine produced the highest level of HI antibody and the most satisfactory protection, whereas concurrent rent vaccination with live and gel vaccine induced poor immune responses. There was no noticeable difference in the efficacy between the live vaccines, Bl and LaSota when simultaneously administered with oil vaccine. Except for oil vaccine, single administration of either live or killed vaccine at day-old produced less than 50% protection at 4 and 8 weeks postvaccination(PV). Oil vaucine alone induced 80% and 70% protection at 4 and 8 week PV, respectively. Concurrent vaccination caused on visible side reaction like respiratory symptoms and did not negatively influence the growth rate of birds until the end of experiment.

  • PDF

Consideration of Cause of Recent Severe Outbreaks of Newcastle Disease in Korea and a Brief Review of Virological Differences, Serological Diagnosis and Administration of a Vaccine (최근의 닭 뉴캣슬병 만연에 따른 원인과 바이러스의 성상, 진단 및 백신 운용에 관한 고찰)

  • 김재흥;송창선
    • Korean Journal of Poultry Science
    • /
    • v.19 no.2
    • /
    • pp.65-76
    • /
    • 1992
  • Since the first outbreaks of Newcastle disease ( ND) in Korea was reported in 1927, the disease has been a major problem in Korean poultry industry. Several attempts related ND prevention and controls have been tried and significantly reduced the ND outbreaks. However, recently frequencies of ND outbreaks have been increased throughout the country since 1988. Many assumptions such as variances of ND virus pathogenicity, decreased efficacy of ND vaccine, incorrect vaccination program etc, has been issued and discussed. Therefore, to clearly understand this recent situation of ND outbreaks in Korea, we reviewed all available past informations related with ND outbreaks in Korea and compared the virulence of recently isolated ND viruses with that of a reference one. Also, we discussed about some problems related with serological diagnosis. administration methods of vaccine and vaccination program.

  • PDF

Studies on the immunization against Newcastle disease virus in Ogol chicken (오골계의 뉴캣슬바이러스 면역원성 조사)

  • 이종훈;김영진;정영균;정영재
    • Korean Journal of Veterinary Service
    • /
    • v.22 no.1
    • /
    • pp.37-42
    • /
    • 1999
  • This study was conducted to determine whether the vaccination programs for the control of Newcastle disease(ND) would affect the immune status of Ogol chicken in Yeonsan, Chungnam province. The results obstained are summerized as followes ; 1. Maternal antibody titers level of Ogol chickes was 2 $log_2$. 2. The efficacy of the Newcastle spray and drinking water vaccine was evaluated by the antibody responses and the protection rates(over 90% ) after challenge with a virulent Newcastle disease vims at 14 days. 3. Spray vaccine caused on visible side reaction like respiratory symptoms, but it is declined of the 4~5 days.

  • PDF

Antibody productivity of HBsAg containing both preS2 and S regions expressed in Chinese hamster ovary cells (Chinese hamster ovary세포에서 발현된 pres2 및 S부위 함유 HBsAg의 항체유발능)

  • 정성균;박정민;이상봉;박동우;김동연;김기호;김홍진
    • YAKHAK HOEJI
    • /
    • v.45 no.6
    • /
    • pp.708-714
    • /
    • 2001
  • Many studies have provided evidences that hepatitis B surface antigen (HBsAg) including preS region could be an ideal candidate for a new hepatitis B virus (HBV) vaccine with higher efficacy. We established CHO cell lines, IY-CHO-2 and IY-CHO-11 expressing high levels of HBsAg containing preS2 and S protein by stable transfection method. These cell lines expressed the correct size (about 1 kb in length) of HBsAg mRNA as expected. The purified protein from the culture supernatants of the clones showed the same sizes as those expressed in native hepatitis B virus (24 kDa, 27 kDa, 34 kDa and 36 kDa). Antibody productivity of CHO-derived HBsAg protein at lower dose challenge was higher than the protein containing S region alone expressed in yeast system. These results indicate that CHO-derived HBsAg protein containing preS2 and S region can be effectively used for a better immune response as a HBV vaccine.

  • PDF

Updates on the coronavirus disease 2019 vaccine and consideration in children

  • Kang, Hyun Mi;Choi, Eun Hwa;Kim, Yae-Jean
    • Clinical and Experimental Pediatrics
    • /
    • v.64 no.7
    • /
    • pp.328-338
    • /
    • 2021
  • Humanity has been suffering from the global severe acute respiratory syndrome coronavirus 2 pandemic that began late in 2019. In 2020, for the first time in history, new vaccine platforms-including mRNA vaccines and viral vector-based DNA vaccines-have been given emergency use authorization, leading to mass vaccinations. The purpose of this article is to review the currently most widely used coronavirus disease 2019 vaccines, investigate their immunogenicity and efficacy data, and analyze the vaccine safety profiles that have been published, to date.